Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Innovative NO Delivery | Beyond Air's LungFit PH system generates nitric oxide from room air, potentially disrupting the traditional canister-based market with enhanced safety and cost-effectiveness |
Financial Tightrope | Explore Beyond Air's strategies to reduce cash burn and reach breakeven by FY2027, while facing revenue projection challenges and the need for additional funding |
Market Expansion Plans | Learn about Beyond Air's efforts to broaden LungFit PH's applications, including a transport-compatible system and potential use in cardiac surgeries |
Analyst Outlook | Roth Capital Partners maintains a Buy rating with a $2.00 price target, reflecting cautious optimism amidst Beyond Air's execution risks and growth potential |
Metrics to compare | XAIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXAIRPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −4.9x | −0.7x | |
PEG Ratio | −0.02 | −0.05 | 0.00 | |
Price/Book | 1.3x | 1.1x | 2.6x | |
Price / LTM Sales | 15.0x | 1.7x | 3.2x | |
Upside (Analyst Target) | 309.8% | 136.2% | 46.6% | |
Fair Value Upside | Unlock | 7.0% | 7.4% | Unlock |